Congestive Heart Failure - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

文章摘要

Noninvasive Imaging for the Evaluation of Diastolic Function: Promises Fulfilled
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block
Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study
Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week

Original Research

2019 May;21(5):665-675.

JOURNAL：Eur J Heart Fail.

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators.

4808

Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF